Next 10 |
2024-07-26 11:32:00 ET Summary Since the MSCI ACWI Value Index underperformed the MSCI ACWI Growth Index by seven percentage points in the second quarter, value stocks have now trailed growth stocks for three quarters in a row. We trimmed several of the Fund’s developed mar...
Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza Canada NewsWire TORONTO , July 26, 2024 /CNW/ - The National Advisory Committee on Immunization's (NACI) annual Statement...
2024-07-26 10:45:00 ET Summary U.S. equity markets rose during the second quarter of 2024, extending the strong market uptrend since 2023. U.S. growth stocks continued to outperform value stocks during the quarter, and the valuation disparity between value and growth stocks widene...
2024-07-25 14:00:42 ET More on Sanofi Sanofi (SNY) Q2 2024 Earnings Call Transcript Sanofi 2024 Q2 - Results - Earnings Call Presentation Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi Non-GAAP EPS of €1.73, revenue of €10.7...
Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season Canada NewsWire TORONTO , July 25, 2024 /CNW/ - The Ontario Ministry of Health has announced a universal public program with Beyfortus ® (nirsevimab...
2024-07-25 12:51:02 ET Sanofi (SNY) Q2 2024 Q2 2024 Earnings Conference Call July 25, 2024 8:30 AM ET Company Participants Thomas Kudsk - Investor Relations Paul Hudson - Chief Executive Officer François Roger - Executive Vice President, Chief Financial Offi...
2024-07-25 07:38:37 ET More on AstraZeneca AstraZeneca Stock: Upgrading From 'Hold' To 'Buy' Ahead Of Q2 2024 Earnings AstraZeneca's Oncology Success: Fueling Future Growth AstraZeneca: The Price Upside Is Exhausted For Now (Rating Downgrade) AstraZeneca beat...
2024-07-25 01:53:09 ET More on Sanofi Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting Sanofi: A Leader In Life-Saving Vaccines And Treatments Sanofi Q1: Wait And See For Now (Downgrade) Kymera announces expansion of KT-474 HS and AD phase 2 studi...
2024-07-23 19:32:16 ET Summary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could rea...
2024-07-23 07:31:42 ET More on Merck Merck: Positive Developments, But Watch The Q2 Earnings Merck: Among The Best Health Care GARP Plays Today Merck & Co., Inc. (MRK) Goldman Sachs 45th Annual Global Healthcare Conference - (Transcript) Kamala Harris' po...
News, Short Squeeze, Breakout and More Instantly...
Fluzone® High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza Canada NewsWire TORONTO , July 26, 2024 /CNW/ - The National Advisory Committee on Immunization's (NACI) annual Statement...
Ontario Ministry of Health Announces a Universal Public Program with Beyfortus® this RSV Season Canada NewsWire TORONTO , July 25, 2024 /CNW/ - The Ontario Ministry of Health has announced a universal public program with Beyfortus ® (nirsevimab...